Dengue virus serotype 1 envelope protein domain III (DENV-1 EDIII)

The Dengue virus serotype 1 envelope protein domain III (DENV-1 EDIII) is a critical structural component of the viral surface, characterized by an immunoglobulin-like fold (UniProt P17758). It plays a primary role in the viral life cycle by mediating attachment to host cell receptors, such as heparan sulfate and DC-SIGN, facilitating viral entry (PubMed: 22952348). As a major target for the host immune system, EDIII contains several potent neutralizing epitopes, making it a focal point for the development of serotype-specific vaccines and therapeutic monoclonal antibodies (PubMed: 15709114). For instance, monoclonal antibodies like 14c10 have been shown to bind specifically to DENV-1 EDIII to neutralize the virus (PubMed: 22722249). However, targeting this domain requires careful consideration of antibody-dependent enhancement (ADE), where sub-neutralizing levels of antibodies can facilitate viral entry into Fc-receptor-bearing cells, potentially worsening the disease (PubMed: 20445044). Research into DENV-1 EDIII aims to produce highly specific inhibitors and immunogens that provide robust protection without inducing cross-reactive, non-neutralizing antibodies that could trigger ADE.

Other names

DENV1 E-DIIIDengue virus type 1 envelope protein domain IIIDENV-1 domain III of the envelope proteinDENV1 ED3

Neutralization of viral infection by blocking the interaction between the virus and host cell receptors, thereby preventing viral entry and fusion (PubMed: 22722249).